← Esperion Therapeutics, Inc. (ESPR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Esperion Therapeutics, Inc. (ESPR)
Pharmaceutical Preparations · market cap $811M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Esperion Therapeutics (ESPR) is a ~$819M market-cap specialty pharma focused on bempedoic acid and related combination therapies for LDL-C reduction and cardiovascular risk. The company has achieved meaningful commercial revenue growth ($75M in 2022 to $403M in 2025) and narrowed its net loss significantly, though it remains unprofitable. With ~$156M cash and a ~17-month runway, the near-term focus is execution on commercialization rather than binary clinical reads.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Bempedoic Acid | Phase 3 | Hyperlipidemias |
| bempedoic acid 180mg | Phase 2 | Hypercholesterolemia |
| Bempedoic acid 180 mg tablet | Phase 3 | Cardiovascular Diseases |
| ETC-1002 | Phase 3 | Hyperlipidemia |
Price & technical context
3-month
+45.9%
6-month
-17.2%
12-month
+158.5%
52-wk range
$1.12–$4.08
vs 50-day MA
+2.7%
vs 200-day MA
+4.1%
Realized vol
83.7%
Max drawdown
-80.9%
Daily closes through 2026-07-10. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ESPR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.